Sana Biotechnology (NASDAQ:SANA) Coverage Initiated at Rodman & Renshaw

Rodman & Renshaw assumed coverage on shares of Sana Biotechnology (NASDAQ:SANA) in a report issued on Wednesday, MarketBeat Ratings reports. The firm issued a buy rating and a $16.00 price target on the stock.

Several other analysts have also weighed in on the company. HC Wainwright restated a buy rating and issued a $12.00 price objective on shares of Sana Biotechnology in a report on Thursday, May 9th. JMP Securities upped their price objective on Sana Biotechnology from $8.00 to $15.00 and gave the company a market outperform rating in a report on Friday, March 1st. One analyst has rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of Moderate Buy and an average price target of $12.75.

Sana Biotechnology Stock Performance

Shares of SANA stock opened at $5.46 on Wednesday. Sana Biotechnology has a 1 year low of $2.74 and a 1 year high of $12.00. The stock has a fifty day moving average of $7.68 and a two-hundred day moving average of $7.38. The firm has a market capitalization of $1.21 billion, a PE ratio of -3.57 and a beta of 1.53.

Sana Biotechnology (NASDAQ:SANA) last announced its quarterly earnings results on Wednesday, May 8th. The company reported ($0.32) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.02). Equities research analysts predict that Sana Biotechnology will post -1.15 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Sana Biotechnology

Hedge funds have recently modified their holdings of the stock. Citigroup Inc. raised its position in Sana Biotechnology by 10.3% during the third quarter. Citigroup Inc. now owns 145,370 shares of the company’s stock valued at $563,000 after buying an additional 13,616 shares during the period. Trexquant Investment LP acquired a new position in Sana Biotechnology during the third quarter valued at $528,000. GSA Capital Partners LLP acquired a new position in Sana Biotechnology during the third quarter valued at $2,091,000. Vanguard Group Inc. raised its position in Sana Biotechnology by 1.2% during the third quarter. Vanguard Group Inc. now owns 9,167,585 shares of the company’s stock valued at $35,479,000 after buying an additional 107,167 shares during the period. Finally, SG Americas Securities LLC acquired a new position in Sana Biotechnology during the fourth quarter valued at $99,000. 88.23% of the stock is owned by hedge funds and other institutional investors.

About Sana Biotechnology

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.